Projecting future drug expenditures - 2008

American Journal of Health-System Pharmacy

Volumn 65, Issue 3, 2008, Pages 234-253

  Hoffman, James M ^a,b   Shah, Nilay D ^c   Vermeulen, Lee C ^d,e   Doloresco, Fred ^f   Grim, Penny ^g   Hunkler, Robert J ^g   Hontz, Karrie M ^g   Schumock, Glen T ^h  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MAYO CLINIC   (United States)

^d University of Wisconsin Health   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UWHC

^g IQVIA   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Costs; Drugs; Economics; Health benefit programs; Prescriptions; United States

Indexed keywords

17 METHYLNALTREXONE; ALENDRONIC ACID; ALVIMOPAN; ANTIVIRUS AGENT; BAYGAM; BENDAMUSTINE; BEVACIZUMAB; BICALUTAMIDE; CARIMUNE; CEFTOBIPROLE; CERTOLIZUMAB PEGOL; CETIRIZINE; CETUXIMAB; DALBAVANCIN; DOCETAXEL; ENOXAPARIN; ERTAVIRINE; ETIRACETAM; FOLINATE CALCIUM; FOSPROPOFOL; GAMMAR P; GEMCITABINE; GRANISETRON; HUMAN IMMUNOGLOBULIN; ICATIBANT; ILOPERIDONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; IODIXANOL; IOHEXOL; IRINOTECAN; ISTRADEFYLLINE; LAMOTRIGINE; LANSOPRAZOLE; LEVOFLOXACIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ONDANSETRON; OXALIPLATIN; OXCARBAZEPINE; PARICALCITOL; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; PRASUGREL; RAMIPRIL; RECLAST; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISPERIDONE; RITUXIMAB; SALMETEROL; SALMETEROL XINAFOATE; SATRAPLATIN; STAVUDINE; TARIBAVIRIN; TELAVANCIN; TRASTUZUMAB; TREANDA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; VERNAKALANT; VILDAGLIPTIN; ZALEPLON; ZEVEN; ZOLEDRONIC ACID; GENERIC DRUG;

DRUG APPROVAL; DRUG COST; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE COST; HOSPITAL COST; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; ARTICLE; ECONOMICS; FORECASTING; HEALTH ECONOMICS; OUTPATIENT DEPARTMENT;

AMBULATORY CARE FACILITIES; DRUG APPROVAL; DRUG COSTS; DRUGS, GENERIC; ECONOMICS, HOSPITAL; FORECASTING;

EID: 38749149250     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070629     Document Type: Review

References (92)

1. IMS Health National Sales Perspectives, November 2007. Analysis conducted by the authors.
2. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting drug expenditures - 2007. Am J Health-Syst Pharm. 2007; 64: 298-314.
3. Poisal JS, Truffer C, Smith S et al. Health spending projections through 2016: modest changes obscure Part D's impact. Health Aff. 2007; 26:w242-53.
4. IMS Health National Prescription Audit, November 2007. Analysis conducted by the authors.
5. Catlin A, Cowan C, Heffler S et al. National health spending in 2005: the slowdown continues. Health Aff. 2007; 26:142-53.
6. Claxton C, Gabel J, DiJiulio B et al. Health benefits in 2007: premium increases fall to an eight year low, while offer rates and coverage remain stable. Health Aff. 2007; 26:1407-16.
7. American Hospital Association. Trends affecting hospitals and health-systems, TrendWatch chartbook, April 2007. www.aha.org/aha/research-and- trends/ trendwatch/2007chartbook.html (accessed 2007 Aug 29).
8. Kaiser Family Foundation. State health facts. http://statehealthfacts. org/cgi-bin/ healthfacts.cgi (accessed 2006 Sep 4).
9. Strunk BC, Ginsburg PB, Banker MI. The effect of population aging on future hospital demand. Health Aff. 2006; 25:w141-9.
10. Cutler DM. The demise of the blockbuster? N Engl J Med. 2007; 356:1292-3.
11. Wadman M. When the party's over. Nature. 2007; 445:13.
12. McKenney JM, Davidson MH, Shear CL et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006; 48:1782-90.
13. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004; 350:1505-15.
14. Tanne JH. Pfizer stops clinical trials of heart drug. BMJ. 2006; 333:1237. News.
15. Berenson A, Harris G. End of drug trial is a big loss for Pfizer and heart patients. N Y Times. 2006; Dec 4:A1.
16. Food and Drug Administration. CDER new molecular entity (NME) drug and new biologic approvals in calendar year 2006. www.fda.gov/Cder/rdmt/ InternetNME06.htm (accessed 2007 Oct 20).
17. Food and Drug Administration. CDER data briefing, 1996-2006 accessible version. www.fda.gov/cder/reports/ CDERDataBriefing1996-2006accessible. htm (accessed 2007 Oct 20).
18. Food and Drug Administration. CDER new molecular entity (NME) drug and new biologic approvals in calendar year 2007, updated through July 31, 2007. www.fda.gov/Cder/rdmt/ InternetNME07.htm (accessed 2007 Oct 20).
19. Sprycel (dasatinib) prescribing information. www.fda.gov/cder/foi/ label/2006/021986lbl.pdf (accessed 2007 Oct 20).
20. Food and Drug Administration. Number of NDAs received, by calendar year. www. fda.gov/Cder/rdmt/numofndareccy.htm (accessed 2007 Oct 20).
21. Food and Drug Administration. CDER original INDs received for calendar years 1986-2006. www.fda.gov/Cder/rdmt/ Cyindrec.htm (accessed 2007 Oct 20).
22. Food and Drug Administration. CDER number of active INDs at the close of calendar years 1986-2006. www.fda.gov/ Cder/rdmt/cyactind.htm (accessed 2007 Oct 20).
23. FDAAA breakdown: a big picture look at a big bill. FDC Rep Pink Sheet. 2007; 69 (Oct 1):6-7.
24. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting drug expenditures - 2004. Am J Health-Syst Pharm. 2004; 61: 145-58.
25. Lee TH. "Me-too" products - friend or foe? N Engl J Med. 2004; 350:211-2. [Erratum, N Engl J Med. 2004; 350:1586.]
26. Rogers EM. Diffusion of innovations. 4th ed. New York: Free Press; 1995.
27. Saul S, Harris G. Years ago, agency was warned of a drug's risks. N Y Times. 2007; May 24:C1.
28. Harris G. FDA remains unsettled in wake of new questions. N Y Times. 2007; May 31:A14.
29. Harris G. FDA issues strictest warning on diabetes drugs. N Y Times. 2007; Jun 7:A1.
30. Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press; 2006.
31. Harris S. Study condemns F.D.A.'s handling of drug safety. N Y Times. 2007; Sep 23:A1.
32. Weiss Smith S. Sidelining safety - the FDA's inadequate response to the IOM. N Engl J Med. 2007; 357:960-3.
33. McClellan M. Drug safety reform at the FDA - pendulum swing or systematic improvement? N Engl J Med. 2007; 356:1700-2.
34. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-71. [Erratum, N Engl J Med. 2007; 357:100.]
35. Drazen JM, Morrissey S, Curfman GD. Rosiglitazone - continued uncertainty about safety. N Engl J Med. 2007; 357:63-4.
36. Nathan DM. Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med. 2007; 357:64-6.
37. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007; 357: 67-9.
38. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007; 147: 578-81.
39. Mulrow CD, Cornell J, Localio AR. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med. 2007; 147:585-7.
40. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298:1189-95.
41. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiac outcomes - an interim analysis. N Engl J Med. 2007; 357:28-38.
42. Harris G. Diabetes drug backed, but with warnings. N Y Times. 2007; Jul 31:A11.
43. Rosiglitazone maleate information. www.fda.gov/cder/drug/infopage/ rosiglitazone/default.htm (accessed 2007 Oct 20).
44. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist. 2007; 12:362-5.
45. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
46. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25:1027-32.
47. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98:708-14.
48. Information on erythropoesis stimulating agents (ESAs). www.fda.gov/cder/ drug/infopage/RHE/default.htm (accessed 2007 Oct 20).
49. ESA labeling should explain hemoglobin target, advisory committee says. FDC Rep Pink Sheet. 2007; 69(Sep 17):3.
50. Pollack A. Medicare eases proposed restrictions on anemia drugs used by cancer patients. N Y Times. 2007; Jul 31:C4.
51. Medicare ESA coverage to re-open? FDC Rep Pink Sheet. 2007; 69(Sep 3):24.
52. Medicare's ESA proposal relies too much on off-label data, Amgen says. FDC Rep Pink Sheet. 2007; 69(Jun 18):21.
53. Costello D. Senators promote Amgen's claim with Medicare; Specter and Lautenberg ask the agency to revisit its limits on coverage of the firm's anemia drugs. Los Angel Times. 2007; Sep 6:C3.
54. Medicare's Amgen seeking ESA dosing algorithm as scripts continue to fall in oncology. FDC Rep Pink Sheet. 2007; 69(Oct 1):17.
55. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health-Syst Pharm. 2005; 62(suppl 3):S5-11.
56. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health-Syst Pharm. 2005; 62(suppl 3):S12-8.
57. Generic Pharmaceutical Association. Industry statistics. www.gphaonline.org/ Content/NavigationMenu/AboutGenerics/ Statistics/default.htm (accessed 2007 Sep 20).
58. Pollack S. Pfizer, hurt by rival generic drugs, will lay off 7,800. N Y Times. 2007; Jan 23:C1.
59. Saul S. More generics slow the surge in drug prices. N Y Times. 2007; Aug 8:A1.
60. Saul S. Generics: an inflation therapy. N Y Times. 2007; Sep 21:C1.
61. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting drug expenditures - 2006. Am J Health-Syst Pharm. 2006; 63:123-38.
62. Haas JS, Phillips KA, Gerstenberger EP et al. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005; 142:891-7.
63. Frank RG. Regulation of follow-on biologics. N Engl J Med. 2007; 357:841-3.
64. Finkelstein JB. Generic biologics may be coming to the marketplace if legislation passes in Congress. J Natl Cancer Inst. 2007; 99:1286-7.
65. Cost savings in generic biotech drugs detailed. Los Angel Times. 2007; Feb 15:C8.
66. Saul S. States, bridling at insulin's cost, push for generics. N Y Times. 2007; Jan 11:A1.
67. Henderson D. Senate bill paves way for generic biologics; compromise aims to speed approval, allay drug makers' fears. Boston Globe. 2007; Jun 23:B5.
68. S.1695. A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes. http://thomas.loc.gov/ cgi-bin/bdquery/ z?d110:SN01695:@@@D&summ2=m& (accessed 2007 Oct 20).
69. Generic anemia drug allowed. N Y Times. 2007; Sep 1:C4.
70. Heffler S. US health spending projections for 2004-2014. Health Aff. 2005; 24:w74-85.
71. Yin W, Basu A, Zhang JX et al. Changes in prescription use and out-of-pocket costs among Medicare eligible adults, 2005-2006. Value Health. 2007; 10(3):A4.
72. Medicare Part D: the first year. Plymouth Meeting, PA: IMS Health; 2007.
73. Centers for Medicare and Medicaid Services. Drug plan finder analysis: Medicare PDP savings compared to cash prices. www. cms.hhs.gov/ prescriptiondrugcovgenIn/ downloads/planfinderanalysis.pdf (accessed 2007 Feb 25).
74. Steinberg M, Bailey K. No bargain: Medicare drug plans deliver high prices. Washington, DC: Families USA; 2007 Jan.
75. Neuman P, Strollo MK, Guterman S et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff. 2007; 26:w630-43.
76. Fein AJ. Managing wholesaler agreements in the fee-for-service era. Am J Health-Syst Pharm. 2007; 64:1153. Editorial.
77. Wholesalers benefit from fee-based contracts, but speculative buying not extinct. FDC Rep Pink Sheet. 2007; 69(Aug 27):12.
78. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006; 355:1409-12.
79. H.P. Acthar Gel (repository corticotropin injection) package insert. www.acthar. com/Pdf/Acthar_PI.pdf (accessed 2007 Sep 20).
80. Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol. 2004; 19:401-4.
81. Stark K. Drug's price up more than $21,000; the hike for H.P. Acthar, which treats a rare childhood disorder, has sparked debate over prescription costs. Phila Inquirer. 2007; Oct 2:C1.
82. Health Resources and Services Administration. Introduction to 340B drug pricing program. www.hrsa.gov/ opa/introduction.htm (accessed 2007 Oct 20).
83. Congressional Budget Office. Prices for brand-name drugs under selected federal programs, June 2005. www. cbo.gov/ftpdocs/64xx/doc6481/06-16- PrescriptDrug.pdf (accessed 2007 Nov 1).
84. Health Resources and Services Administration. Notice regarding the 340B drug pricing program; children's hospitals. www.hrsa.gov/opa/frn070907.htm (accessed 2007 Oct 20).
85. S.1376 title: a bill to amend the Public Health Service Act to revise and expand the drug discount program under section 340B of such Act to improve the provision of discounts on drug purchases for certain safety net providers. http.V/thomas. loc.gov/cgi-bin/bdquery/z?d110:s.01376 (accessed 2007 Oct 20).
86. 2006 Drug trend report. St. Louis: Express Scripts; 2007 Apr.
87. Drug trend report: humanomics. Franklin Lakes, NJ: Medco Health; 2007 May.
88. Weir HK, Thun MJ, Hankey BF et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003; 95:1276-99.
89. Conmy D. The quest for population: with US prescription drug sales falling to 5.4% in 2005, the challenge for pharmaceutical companies is to balance resources with results. Med Mark Media. 2006; 41:40-9.
90. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2005. Am J Health-Syst Pharm. 2005; 62:149-67.
91. Armitstead J, Loyd L, Pane F et al. Implications of the specialty drug marketplace for health-system pharmacy: a round-table discussion. Am J Health-Syst Pharm. 2007; 64:2364-72.
92. Shane R. Management of chronic diseases in the 21st century: the emerging role of specialty pharmacies. Am J Health-Syst Pharm. 2007; 64:2382-5.